Literature DB >> 32311803

Alopecia areata development in atopic dermatitis patients treated with dupilumab.

S Ständer1, Y Trense2, D Thaçi2, R J Ludwig3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32311803     DOI： 10.1111/jdv.16493

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  6 in total

Review 1.  Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.

Authors:  Cheng Zhou; Xiangqian Li; Chen Wang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-17       Impact factor: 8.667

2.  Improvement of atopic dermatitis and alopecia universalis with dupilumab.

Authors:  Lama Alotaibi; Abdulrahman Alfawzan; Raghad Alharthi; Afaf Al Sheikh
Journal:  Dermatol Reports       Date:  2021-12-28

Review 3.  Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review.

Authors:  Tejas P Joshi; Hannah Y Wang; Prazwal Athukuri; Sarah Bohac; Morgan A Farr; Darien Hinson; Justin A Kahla; Nasim Khalfe; Dylan B McBee; Rachel Stroh; Nicole Walters; Vicky Ren
Journal:  Am J Clin Dermatol       Date:  2022-05-23       Impact factor: 6.233

4.  Rapid Enlargement of Vitiligo Vulgaris after Initiation of Dupilumab for Atopic Dermatitis: A Case Report.

Authors:  Shintaro Takeoka; Masahiro Kamata; Ikumi Yokoi; Aya Takehara; Yayoi Tada
Journal:  Acta Derm Venereol       Date:  2021-10-28       Impact factor: 3.875

Review 5.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

6.  Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.

Authors:  Sunny Park; So Hyang Park; Young Joo Byun; Soo An Choi
Journal:  PLoS One       Date:  2022-07-27       Impact factor: 3.752
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.